John F. D. Dipersio, MD, PhD | Authors

Treatment Approaches Using Ruxolitinib in GVHD

May 12, 2022

In a discussion on the use of ruxolitinib in GVHD, experts consider the potential role of dose reductions or dose holds to mitigate toxicity and comment on experiences with combining or sequencing therapies in later lines of treatment.

Additional Approaches for Steroid-Refractory Chronic GVHD

May 12, 2022

Expert panelists comment on additional treatment options for significant steroid-refractory chronic GVHD following initial therapeutic intervention, including rechallenging with prophylactic agents or initiating B-cell therapy.

Clinical Scenario 1: First- and Second-Line Treatment for GVHD

April 28, 2022

John F. DiPersio, MD, PhD, presents the clinical scenario of a 71-year-old patient postmatched unrelated donor HSCT, and the panel discusses first- and second-line treatment approaches including topical and systemic therapies.

Chronic GVHD Risk Factors and Prevention

April 14, 2022

Panelists consider key risk factors for chronic GVHD, including the degree of donor transplant matching, patient age, intensity of conditioning, use of ablative doses of total-body radiation, and presence of acute GVHD.